Mast Cell Activation Syndrome

Developing an understanding of complex, chronic cases of Mast Cell Activation Syndrome (MCAS) is essential as patients with MCAS often remain undiagnosed and symptomatic for decades. The prevalence of MCAS is expected to rise significantly in the next decade due to COVID-19 (1).

Understanding this disorder is essential to restoring wellness in chronic illness. Building this knowledge dramatically increases clinical outcomes in pain syndromes, and fatigue presentations.

First reported in 2007, MCAS is a multifactorial, usually somatically polygenic chronic multisystem disorder with inflammatory and allergic themes and has an estimated prevalence of 17% (2).

Find out all you need to know about how MCAS influences heath including 3 of the top presentations within clinical practice – pain, migraine, and fatigue.

We urgently need to develop clinical understanding of how to reduce the long-term impact of this growing health crisis through integrative and environmental health interventions. Reduce the impact of MCAS on a person’s quality of life.

Join internationally renowned Beth O’Hara, a successful functional naturopathic clinician and co-founder of the Mast Cell 360 Program, a powerful, holistic health program for MCAS.

Find out why:

• People who have MCAS go undiagnosed
• How MCAS can be supported by adopting a holistic approach to health

This webinar is Part 1 of 3 with Beth O’Hara, the other two presentations are both available in the Optimising Immune Function learning module.

acnem Members receive monthly webinars for FREE located in the Member Resources page! Join acnem today!

1. Weinstock, L. B., Brook, J. B., Walters, A. S., Goris, A., Afrin, L. B., & Molderings, G. J. (2021). Mast cell activation symptoms are prevalent in Long-COVID. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 112, 217–226. https://doi.org/10.1016/j.ijid.2021.09.043
2. Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., Dubravec, M. S., Guggenheim, A. G., Hindman, K. J., Hoffman, B., Kaufman, D. L., Kratzer, S. J., Lee, T. M., Marantz, M. S., Maxwell, A. J., McCann, K. K., … Molderings, G. J. (2020). Diagnosis of mast cell activation syndrome: a global “consensus-2”. Diagnosis (Berlin, Germany), 8(2), 137–152. https://doi.org/10.1515/dx-2020-0005